Anthem Biosciences Limited
Bajaj Allianz Life Insurance bought 12,08,379 shares of Anthem Biosciences Limited for ₹90.00 Cr at ₹744.80 apiece in a block deal.
A biotechnology company providing contract research, development, and manufacturing services alongside specialty ingredients production. Established in 2006, the company serves pharmaceutical and nutraceutical sectors through its integrated CRDMO capabilities and custom synthesis expertise. Its distinctive position lies in combining comprehensive development expertise with in-house manufacturing facilities, enabling end-to-end solutions for clients requiring specialized ingredient formulation, process optimization, and commercial-scale production services.
Now wholly owned by Bajaj Finserv after the Bajaj Group bought out Allianz SE's 26% stake in March 2025 for Rs 24,180 crore. Total AUM over Rs 1.2 lakh crore. Flagship Pure Stock Fund manages over Rs 7,200 crore as a Shariah-compliant Indian equity book. Active investor across large and midcap names through ULIP and group fund vehicles.